Evidence map›Paper›PMID 37004637›Full record

ArticleMolecular and cellular biochemistry2024

Large DNA fragment knock-in and sequential gene editing in Plasmodium falciparum: a preliminary study using suicide-rescue-based CRISPR/Cas9 system.

Junnan Lu, Ying Tong, Rui Dong, Yijun Yang, Wen Hu, Minghong Zhang, Quan Liu, Siting Zhao, John H Adams, Li Qin and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Junnan LuLaboratory of Pathogen Biology, State Key Laboratory of Respiratory Disease, Center for Infection and Immunity, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
Ying TongCAS Lamvac Biotech Co., Ltd., No. 3 Lanyue Road, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
Rui DongCAS Lamvac Biotech Co., Ltd., No. 3 Lanyue Road, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
Yijun YangLaboratory of Pathogen Biology, State Key Laboratory of Respiratory Disease, Center for Infection and Immunity, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
Wen HuCAS Lamvac Biotech Co., Ltd., No. 3 Lanyue Road, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
Minghong ZhangCAS Lamvac Biotech Co., Ltd., No. 3 Lanyue Road, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
Quan LiuLaboratory of Pathogen Biology, State Key Laboratory of Respiratory Disease, Center for Infection and Immunity, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
Siting ZhaoLaboratory of Pathogen Biology, State Key Laboratory of Respiratory Disease, Center for Infection and Immunity, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
John H AdamsCAS Lamvac Biotech Co., Ltd., No. 3 Lanyue Road, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China.
Li QinLaboratory of Pathogen Biology, State Key Laboratory of Respiratory Disease, Center for Infection and Immunity, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China. qin_li@cas-lamvac.com.
Xiaoping ChenLaboratory of Pathogen Biology, State Key Laboratory of Respiratory Disease, Center for Infection and Immunity, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, Guangdong Province, People's Republic of China. chen_xiaoping@gibh.ac.cn.
Guangzhou Institutes of Biomedicine and Health · CNState Key Laboratory of Respiratory Disease · CNGuangzhou Regenerative Medicine and Health Guangdong Laboratory · CNKey Laboratory of Guangdong Province · CNUniversity of South Florida · US

Funding

Chemogenomic Profiling of Plasmodium Falciparum Responses and ResistanceR01AI117017 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI ADAMS, JOHN H · 2015 to 2025
$6.9M
NIAID NIH HHS R01 AI117017
6 · The paper itself

Abstract

CRISPR/Cas9 technology applied to Plasmodium falciparum offers the potential to greatly improve gene editing, but such expectations including large DNA fragment knock-ins and sequential gene editing have remained unfulfilled. Here, we achieved a major advance in addressing this challenge, especially for creating large DNA fragment knock-ins and sequential editing, by modifying our suicide-rescue-based system that has already been demonstrated to be highly efficient for conventional gene editing. This improved approach was confirmed to mediate efficient knock-ins of DNA fragments up to 6.3 kb, to produce "marker-free" genetically engineered parasites and to show potential for sequential gene editing. This represents an important advancement in establishing platforms for large-scale genome editing, which might gain a better understanding of gene function for the most lethal cause of malaria and contribute to adjusting synthetic biology strategies to live parasite malaria vaccine development. Site-directed knock-in of large DNA fragments is highly efficient using suicide-rescue-based CRISPR/Cas9 system, and sequential gene insertion is feasible but further confirmation is still needed.

Indexed as

Gene EditingMalariaCRISPR-Cas SystemsDNAHumansPlasmodium falciparumDNACRISPR/Cas9Large DNA fragmentMarker-freePlasmodium falciparumSequential gene editing

Identifiers

PMID37004637
PMCPMC10066980
OpenAlexW4362520543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.